Table S2. ASAS20 and ASAS40 responses according to ADA status at week 30.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>n</th>
<th>N</th>
<th>(%)</th>
<th>Odds ratio [1]</th>
<th>95% CI of the odds ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ADA positive</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASAS20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CT-P13 5 mg/kg</td>
<td>14</td>
<td>28</td>
<td>50.0</td>
<td>0.47</td>
<td>(0.14, 1.53)</td>
</tr>
<tr>
<td>INX 5 mg/kg</td>
<td>17</td>
<td>26</td>
<td>65.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goodness-of-fit test (p-value0.487) [2]</td>
<td>.</td>
<td>.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASAS40</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CT-P13 5 mg/kg</td>
<td>12</td>
<td>28</td>
<td>42.9</td>
<td>1.45</td>
<td>(0.45, 4.70)</td>
</tr>
<tr>
<td>INX 5 mg/kg</td>
<td>10</td>
<td>26</td>
<td>38.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goodness-of-fit test (p-value0.939) [2]</td>
<td>.</td>
<td>.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ADA negative</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASAS20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CT-P13 5 mg/kg</td>
<td>65</td>
<td>84</td>
<td>77.4</td>
<td>1.15</td>
<td>(0.57, 2.31)</td>
</tr>
<tr>
<td>INX 5 mg/kg</td>
<td>67</td>
<td>90</td>
<td>74.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goodness-of-fit test (p-value0.488) [2]</td>
<td>.</td>
<td>.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASAS40</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CT-P13 5 mg/kg</td>
<td>46</td>
<td>84</td>
<td>54.8</td>
<td>1.18</td>
<td>(0.65, 2.15)</td>
</tr>
<tr>
<td>INX 5 mg/kg</td>
<td>45</td>
<td>90</td>
<td>50.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goodness-of-fit test (p-value0.93) [2]</td>
<td>.</td>
<td>.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: N = the number of subjects with an assessment. n = the number of subjects with the event. (%) = n/N*100. INX = innovator infliximab

[1] The odds ratio was estimated using a logistic regression model with treatment as a fixed effect, and region and baseline BASDAI score as covariates. An odds ratio of >1 indicates an increased odds in favor of CT-P13 5mg/kg.

[2] The p-value is calculated using the Hosmer-Lemeshow test for the goodness-of-fit of the logistic regression model. The test is significant at the 5% level.